Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)

Katelyn A. Pastick; Elizabeth C. Okafor; Fan Wang; Sarah M. Lofgren; Caleb P. Skipper; Melanie R. Nicol; Matthew F. Pullen; Radha Rajasingham; Emily G. McDonald; Todd C. Lee; Ilan S. Schwartz; Lauren E. Kelly; Sylvain A. Lother; Oriol Mitjà; Emili Letang; Mahsa Abassi; David R. Boulware

doi:10.1093/ofid/ofaa130

Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)

Katelyn A. Pastick, Elizabeth C. Okafor, Fan Wang, Sarah M. Lofgren, Caleb P. Skipper, Melanie R. Nicol, Matthew F. Pullen, Radha Rajasingham, Emily G. McDonald, Todd C. Lee, Ilan S. Schwartz, Lauren E. Kelly, Sylvain A. Lother, Oriol Mitjà, Emili Letang, Mahsa Abassi, David R. Boulware

Research output: Contribution to journal › Review article › peer-review

148 Scopus citations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.

Original language	English (US)
Article number	ofaa130
Journal	Open Forum Infectious Diseases
Volume	7
Issue number	4
DOIs	https://doi.org/10.1093/ofid/ofaa130
State	Published - Mar 16 2020

Bibliographical note

Publisher Copyright:
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.

Keywords

“chloroquine
” “SARS-CoV-2.”
” “clinical trials
” “coronavirus
”“COVID-19
”“Hydroxychloroquine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1093/ofid/ofaa130

OpenUrl availability

Full text

Cite this

Pastick, K. A., Okafor, E. C., Wang, F., Lofgren, S. M., Skipper, C. P., Nicol, M. R., Pullen, M. F., Rajasingham, R., McDonald, E. G., Lee, T. C., Schwartz, I. S., Kelly, L. E., Lother, S. A., Mitjà, O., Letang, E., Abassi, M., & Boulware, D. R. (2020). Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases, 7(4), Article ofaa130. https://doi.org/10.1093/ofid/ofaa130

Pastick, KA, Okafor, EC, Wang, F, Lofgren, SM , Skipper, CP , Nicol, MR , Pullen, MF , Rajasingham, R, McDonald, EG, Lee, TC, Schwartz, IS, Kelly, LE, Lother, SA, Mitjà, O, Letang, E, Abassi, M & Boulware, DR 2020, 'Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)', Open Forum Infectious Diseases, vol. 7, no. 4, ofaa130. https://doi.org/10.1093/ofid/ofaa130

@article{f5816fa75545482283244615b4271014,

title = "Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)",

abstract = "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.",

keywords = "“chloroquine, ” “SARS-CoV-2.”, ” “clinical trials, ” “coronavirus, ”“COVID-19, ”“Hydroxychloroquine",

author = "Pastick, {Katelyn A.} and Okafor, {Elizabeth C.} and Fan Wang and Lofgren, {Sarah M.} and Skipper, {Caleb P.} and Nicol, {Melanie R.} and Pullen, {Matthew F.} and Radha Rajasingham and McDonald, {Emily G.} and Lee, {Todd C.} and Schwartz, {Ilan S.} and Kelly, {Lauren E.} and Lother, {Sylvain A.} and Oriol Mitj{\`a} and Emili Letang and Mahsa Abassi and Boulware, {David R.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",

year = "2020",

month = mar,

day = "16",

doi = "10.1093/ofid/ofaa130",

language = "English (US)",

volume = "7",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Review

T2 - Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)

AU - Pastick, Katelyn A.

AU - Okafor, Elizabeth C.

AU - Wang, Fan

AU - Lofgren, Sarah M.

AU - Skipper, Caleb P.

AU - Nicol, Melanie R.

AU - Pullen, Matthew F.

AU - Rajasingham, Radha

AU - McDonald, Emily G.

AU - Lee, Todd C.

AU - Schwartz, Ilan S.

AU - Kelly, Lauren E.

AU - Lother, Sylvain A.

AU - Mitjà, Oriol

AU - Letang, Emili

AU - Abassi, Mahsa

AU - Boulware, David R.

N1 - Publisher Copyright: © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/ by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.

PY - 2020/3/16

Y1 - 2020/3/16

N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.

AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.

KW - “chloroquine

KW - ” “SARS-CoV-2.”

KW - ” “clinical trials

KW - ” “coronavirus

KW - ”“COVID-19

KW - ”“Hydroxychloroquine

UR - http://www.scopus.com/inward/record.url?scp=85083885814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083885814&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofaa130

DO - 10.1093/ofid/ofaa130

M3 - Review article

C2 - 32363212

AN - SCOPUS:85083885814

SN - 2328-8957

VL - 7

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 4

M1 - ofaa130

ER -

Review: Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this